GURUFOCUS.COM » STOCK LIST » USA » NAS » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Cash From Discontinued Investing Activities
Switch to:

Biomarin Pharmaceutical (NAS:BMRN) Cash From Discontinued Investing Activities

: $0 Mil (TTM As of Jun. 2023)
View and export this data going back to 1999. Start your Free Trial

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Biomarin Pharmaceutical's cash from discontinued investing activities for the three months ended in Jun. 2023 was $0 Mil. It means Biomarin Pharmaceutical received $0 Mil from discontinued investing activities. Biomarin Pharmaceutical's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Jun. 2023 was $0 Mil.

Biomarin Pharmaceutical Cash From Discontinued Investing Activities Historical Data

The historical data trend for Biomarin Pharmaceutical's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash From Discontinued Investing Activities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash From Discontinued Investing Activities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (NAS:BMRN) Business Description

Biomarin Pharmaceutical logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Cash From Discontinued Investing Activities
Comparable Companies
NAS:INCY NAS:BGNE NAS:RPRX NAS:LEGN NAS:SRPT NAS:ALNY NAS:TECH NAS:UTHR NAS:JAZZ NAS:ROIV OCSE:NOVO B NAS:VRTX NAS:REGN ASX:CSL NAS:SGEN NAS:MRNA XKRX:207940 XBRU:ARGX NAS:BNTX HKSE:02269
Traded in Other Exchanges
BMRN:Mexico BM8:Germany BM8:Germany BM8:Germany B1MR34:Brazil BMRN:Austria
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Executives
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Andrea Acosta officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST, SAN RAFAEL CA 94901
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Willard H Dere director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Daniel K Spiegelman officer: EVP, Chief Financial Officer MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Kenneth Bate director C/O MILLENNIUM PHARMACEUTICALS INC, 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139